Progress on RNAi-based molecular medicines

References

• FireAXuSMontgomeryMKKostasSADriverSEMelloCCPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature199839166698068119486653
   PubMed Web of Science ®Google Scholar
• HannonGJRNA interferenceNature2002418689424425112110901
   PubMed Web of Science ®Google Scholar
• MeisterGTuschlTMechanisms of gene silencing by double-stranded RNANature2004431700634334915372041
   PubMed Web of Science ®Google Scholar
• NovinaCDSharpPAThe RNAi revolutionNature2004430699616116415241403
   PubMed Web of Science ®Google Scholar
• PushparajPNAarthiJJManikandanJKumarSDsiRNA, miRNA, and shRNA: in vivo applicationsJ Dent Res20088711992100318946005
   PubMed Web of Science ®Google Scholar
• DavidsonBLMcCrayPBJrCurrent prospects for RNA interference-based therapiesNat Rev Genet201112532934021499294
   PubMed Web of Science ®Google Scholar
• Valencia-SanchezMALiuJHannonGJParkerRControl of translation and mRNA degradation by miRNAs and siRNAsGenes Dev200620551552416510870
   PubMed Web of Science ®Google Scholar
• BartelDPMicroRNAs: genomics, biogenesis, mechanism, and functionCell2004116228129714744438
   PubMed Web of Science ®Google Scholar
• LundESheetsMDImbodenSBDahlbergJELimiting Ago protein restricts RNAi and microRNA biogenesis during early development in Xenopus laevisGenes Dev201125111121113121576259
   PubMed Web of Science ®Google Scholar
• ElbashirSMLendeckelWTuschlTRNA interference is mediated by 21- and 22-nucleotide RNAsGenes Dev200115218820011157775
   PubMed Web of Science ®Google Scholar
• ZamorePDTuschlTSharpPABartelDPRNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervalsCell20001011253310778853
   PubMed Web of Science ®Google Scholar
• LewisBPShihIHJones-RhoadesMWBartelDPBurgeCBPrediction of mammalian microRNA targetsCell2003115778779814697198
   PubMed Web of Science ®Google Scholar
• EulalioAHuntzingerEIzaurraldeEGetting to the root of miRNA-mediated gene silencingCell2008132191418191211
   PubMed Web of Science ®Google Scholar
• FabianMRSonenbergNFilipowiczWRegulation of mRNA translation and stability by microRNAsAnnu Rev Biochem20107935137920533884
   PubMed Web of Science ®Google Scholar
• BhattacharyyaSNHabermacherRMartineUClossEIFilipowiczWRelief of microRNA-mediated translational repression in human cells subjected to stressCell200612561111112416777601
   PubMed Web of Science ®Google Scholar
• LiuGWong-StaalFLiQXRecent development of RNAi in drug target discovery and validationDrug Discov Today Technol200633293300
   Google Scholar
• ElbashirSMHarborthJWeberKTuschlTAnalysis of gene function in somatic mammalian cells using small interfering RNAsMethods200226219921312054897
   PubMed Web of Science ®Google Scholar
• LinaWChonggangYDevelopment and applications of RNAi technology in drug researchChin Bull Life Sci200719199213
   Google Scholar
• ReynoldsALeakeDBoeseQScaringeSMarshallWSKhvorovaARational siRNA design for RNA interferenceNat Biotechnol200422332633014758366
   PubMed Web of Science ®Google Scholar
• HarborthJElbashirSMVandenburghKSequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencingAntisense Nucleic Acid Drug Dev20031328310512804036
   PubMedGoogle Scholar
• ShiraneDSugaoKNamikiSTanabeMIinoMHiroseKEnzymatic production of RNAi libraries from cDNAsNat Genet200436219019614704669
   PubMed Web of Science ®Google Scholar
• HeroldMJvan den BrandtJSeiblerJReichardtHMInducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic ratsProc Natl Acad Sci U S A200810547185071851219017805
   PubMed Web of Science ®Google Scholar
• LiJHuangLTargeted delivery of RNAi therapeutics for cancer therapyNanomedicine (Lond)20105101483148621143026
   PubMed Web of Science ®Google Scholar
• TuschlTExpanding small RNA interferenceNat Biotechnol200220544644811981553
   PubMed Web of Science ®Google Scholar
• BrummelkampTRBernardsRAgamiRA system for stable expression of short interfering RNAs in mammalian cellsScience2002296556755055311910072
   PubMed Web of Science ®Google Scholar
• TiscorniaGSingerOIkawaMVermaIMA general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNAProc Natl Acad Sci U S A200310041844184812552109
   PubMed Web of Science ®Google Scholar
• RubinsonDADillonCPKwiatkowskiAVA lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interferenceNat Genet200333340140612590264
   PubMed Web of Science ®Google Scholar
• ChenZStocktonJMathisDBenoistCModeling CTLA4-linked autoimmunity with RNA interference in miceProc Natl Acad Sci U S A200610344164001640517060611
   PubMed Web of Science ®Google Scholar
• MatsukuraSJonesPATakaiDEstablishment of conditional vectors for hairpin siRNA knockdownsNucleic Acids Res20033115e7712888529
   PubMed Web of Science ®Google Scholar
• ShengYLinCCYueJGeneration and characterization of a Tet-On (rtTA-M2) transgenic ratBMC Dev Biol2010101720158911
   PubMed Web of Science ®Google Scholar
• SeiblerJKleinriddersAKüter-LuksBNiehavesSBrüningJCSchwenkFReversible gene knockdown in mice using a tight, inducible shRNA expression systemNucleic Acids Res2007357e5417376804
   PubMed Web of Science ®Google Scholar
• AnastassiadisKKimJDaigleNSprengelRSchölerHRStewartAFA predictable ligand regulated expression strategy for stably integrated transgenes in mammalian cells in cultureGene2002298215917212426104
   PubMed Web of Science ®Google Scholar
• SzymczakALVignaliDADevelopment of 2A peptide-based strategies in the design of multicistronic vectorsExpert Opin Biol Ther20055562763815934839
   PubMed Web of Science ®Google Scholar
• AbdelmawlaSGuoSZhangLPharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic deliveryMol Ther20111971312132221468004
   PubMed Web of Science ®Google Scholar
• WoodleMCLuPYNanoparticles deliver RNAi therapyMater Today200588 Suppl 13441
   Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• van den BoornJGSchleeMCochCHartmannGSiRNA delivery with exosome nanoparticlesNat Biotechnol201129432532621478846
   PubMed Web of Science ®Google Scholar
• LaresMRRossiJJOuelletDLRNAi and small interfering RNAs in human disease therapeutic applicationsTrends Biotechnol2010281157057920833440
   PubMed Web of Science ®Google Scholar
• SuttonDKimSShuaiXEfficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitroInt J Nanomedicine20061215516217722531
   PubMed Web of Science ®Google Scholar
• WuYWangWChenYThe investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitroInt J Nanomedicine2010512913620309399
   PubMed Web of Science ®Google Scholar
• YamamichiKUeharaYKitamuraNNakaneYHiokiKIncreased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancerInt J Cancer19987932562629645347
   PubMed Web of Science ®Google Scholar
• KurozumiKNishidaTNakaoKNakaharaMTsujimotoMExpression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancerWorld J Surg19982288538579673558
   PubMed Web of Science ®Google Scholar
• MiyoshiHBlomerUTakahashiMGageFHVermaIMDevelopment of a self-inactivating lentivirus vectorJ Virol19987210815081579733856
   PubMed Web of Science ®Google Scholar
• VandenDriesscheTThorrezLNaldiniLLentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivoBlood2002100381382212130491
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-AbinaSVon KalleCSchmidtMLMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1Science2003302564441541914564000
   PubMed Web of Science ®Google Scholar
• HannonGJRossiJJUnlocking the potential of the human genome with RNA interferenceNature2004431700637137815372045
   PubMed Web of Science ®Google Scholar
• RaoulCAbbas-TerkiTBensadounJCLentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALSNat Med2005114342342815768028
   PubMed Web of Science ®Google Scholar
• McKinleyMPBoltonDCPrusinerSBA protease-resistant protein is a structural component of the Scrapie prionCell198335157626414721
   PubMed Web of Science ®Google Scholar
• BoltonDMcKinleyMPrusinerSIdentification of a protein that purifies with the scrapie prionScience19822184579130913116815801
   PubMed Web of Science ®Google Scholar
• GieseABrownDRGroschupMHFeldmannCHaistIKretzschmarHARole of microglia in neuronal cell death in prion diseaseBrain Pathol1998834494579669696
   PubMed Web of Science ®Google Scholar
• BuelerHRaeberASailerAFischerMAguzziAWeissmannCHigh prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP geneMol Med19941119308790598
   PubMed Web of Science ®Google Scholar
• PfeiferAEigenbrodSAl-KhadraSLentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected miceJ Clin Invest2006116123204321017143329
   PubMed Web of Science ®Google Scholar
• MallucciGDickinsonALinehanJKlöhnPCBrandnerSCollingeJDepleting neuronal PrP in prion infection prevents disease and reverses spongiosisScience2003302564687187414593181
   PubMed Web of Science ®Google Scholar
• GallozziMChapuisJLe ProvostFPrnp knockdown in transgenic mice using RNA interferenceTransgenic Res200817578379118350371
   PubMed Web of Science ®Google Scholar
• PulfordBReimNBellALiposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell culturesPLoS One201056e1108520559428
   PubMed Web of Science ®Google Scholar
• BergerEAMurphyPMFarberJMChemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and diseaseAnn Rev Immunol199917165770010358771
   PubMed Web of Science ®Google Scholar
• MooreJPTrkolaADragicTCo-receptors for HIV-1 entryCurr Opin Immunol1997945515629287172
   PubMed Web of Science ®Google Scholar
• MosierDVirus and target cell evolution in human immunodeficiency virus type 1 infectionImmunol Res200021225325810852125
   PubMed Web of Science ®Google Scholar
• SimmonsGReevesJDHibbittsSCo-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligandsImmunol Rev2000177111212611138769
   PubMed Web of Science ®Google Scholar
• O’BrienSJNelsonGWHuman genes that limit AIDSNat Genet200436656557415167933
   PubMed Web of Science ®Google Scholar
• SmithMWDeanMCarringtonMContrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE StudyScience199727753289599659252328
   PubMed Web of Science ®Google Scholar
• ShimizuSHongPArumugamBA highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse modelBlood201011581534154420018916
   PubMed Web of Science ®Google Scholar
• ZhangSZhaoBJiangHWangBMaBCationic lipids and polymers mediated vectors for delivery of siRNAJ Control Release2007123111017716771
   PubMed Web of Science ®Google Scholar
• AndersenMOHowardKAPaludanSRBesenbacherFKjemsJDelivery of siRNA from lyophilized polymeric surfacesBiomaterials200829450651217950838
   PubMed Web of Science ®Google Scholar
• KumarPWuHMcBrideJLTransvascular delivery of small interfering RNA to the central nervous systemNature20074487149394317572664
   PubMed Web of Science ®Google Scholar
• LafonMRabies virus receptorsJ Neurovirol2005111828715804965
   PubMed Web of Science ®Google Scholar
• MorrisseyDVLockridgeJAShawLPotent and persistent in vivo anti-HBV activity of chemically modified siRNAsNat Biotechnol20052381002100716041363
   PubMed Web of Science ®Google Scholar
• RichardsDIvanisevicAInorganic material coatings and their effect on cytotoxicityChem Soc Rev20124162052206022116515
   PubMed Web of Science ®Google Scholar
• RippelRASeifalianAMGold revolution – gold nanoparticles for modern medicine and surgeryJ Nanosci Nanotechnol20111153740374821780364
   PubMed Web of Science ®Google Scholar
• GhoshPHanGDeMKimCKRotelloVMGold nanoparticles in delivery applicationsAdv Drug Deliv Rev200860111307131518555555
   PubMed Web of Science ®Google Scholar
• GuoSHuangYJiangQEnhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyteACS Nano2010495505551120707386
   PubMed Web of Science ®Google Scholar
• ChenAMTaratulaOWeiDLabile catalytic packaging of DNA/siRNA: control of gold nanoparticles “out” of DNA/siRNA complexesACS Nano2010473679368820521827
   PubMed Web of Science ®Google Scholar
• ThomasMKlibanovAMConjugation to gold nanoparticles enhances polyethylenimine’s transfer of plasmid DNA into mammalian cellsProc Natl Acad Sci U S A2003100169138914312886020
   PubMed Web of Science ®Google Scholar
• RosiNLGiljohannDAThaxtonCSLytton-JeanAKRHanMSMirkinCAOligonucleotide-modified gold nanoparticles for intracellular gene regulationScience200631257761027103016709779
   PubMed Web of Science ®Google Scholar
• ElbakryAZakyALieblRRachelRGoepferichABreunigMLayer-by-layer assembled gold nanoparticles for siRNA deliveryNano Lett2009952059206419331425
   PubMed Web of Science ®Google Scholar
• LeeJSGreenJJLoveKTSunshineJLangerRAndersonDGGold, poly(beta-amino ester) nanoparticles for small interfering RNA deliveryNano Lett2009962402240619422265
   PubMed Web of Science ®Google Scholar
• SongWJDuJZSunTMZhangPZWangJGold nanoparticles capped with polyethyleneimine for enhanced siRNA deliverySmall20106223924619924738
   PubMed Web of Science ®Google Scholar
• ZuckermanJEChoiCHJHanHDavisMEPolycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membraneProc Natl Acad Sci U S A201210983137314222315430
   PubMed Web of Science ®Google Scholar
• KongWBaeKJoSKimJParkTCationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehiclesPharm Res201229236237421842305
   PubMed Web of Science ®Google Scholar
• SokolovKFollenMAaronJReal-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticlesCancer Res20036391999200412727808
   PubMed Web of Science ®Google Scholar
• XiDLuoXNingQLuQYaoKLiuZThe detection of HBV DNA with gold nanoparticle gene probesJournal of Nanjing Medical University2007214207212
   Google Scholar
• BaptistaPVKoziol-MontewkaMPaluch-OlesJDoriaGFrancoRGold nanoparticle probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samplesClin Chem20065271433143416798971
   PubMed Web of Science ®Google Scholar
• GeorganopoulouDGChangLNamJMNanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s diseaseProc Natl Acad Sci U S A200510272273227615695586
   PubMed Web of Science ®Google Scholar
• MahmoudKALuongJHTImpedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrodeAnal Chem200880187056706218707132
   PubMed Web of Science ®Google Scholar
• GuoPEricksonSAndersonDA small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNAScience198723648026906943107124
   PubMed Web of Science ®Google Scholar
• HoeprichSGuoPComputer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motorJ Biol Chem200227723207942080311886855
   PubMed Web of Science ®Google Scholar
• KhaledAGuoSLiFGuoPControllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnologyNano Lett2005591797180816159227
   PubMed Web of Science ®Google Scholar
• ChenCShengSShaoZGuoPA dimer as a building block in assembling RNAJ Biol Chem200027523175101751610748150
   PubMed Web of Science ®Google Scholar
• ZhangCLeeCSGuoPThe proximate 5′ and 3′ ends of the 120-base viral RNA (pRNA) are crucial for the packaging of bacteriophage Ø29 DNAVirology1994201177858178491
   PubMed Web of Science ®Google Scholar
• GarverKGuoPBoundary of pRNA functional domains and minimum pRNA sequence requirement for specific connector binding and DNA packaging of phage phi29RNA199739106810799292504
   PubMed Web of Science ®Google Scholar
• ReidRJBodleyJWAndersonDCharacterization of the prohead-pRNA interaction of bacteriophage phi 29J Biol Chem19942697515751628106496
   PubMed Web of Science ®Google Scholar
• ChenCZhangCGuoPSequence requirement for hand-in-hand interaction in formation of RNA dimers and hexamers to gear phi29 DNA translocation motorRNA19995680581810376879
   PubMed Web of Science ®Google Scholar
• ZhangCTrottierMGuoPCircularly permuted viral pRNA active and specific in the packaging of bacteriophage φ 29 DNAVirology199520724424517533964
   PubMed Web of Science ®Google Scholar
• GuoSTschammerNMohammedSGuoPSpecific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNAHum Gene Ther20051691097110916149908
   PubMed Web of Science ®Google Scholar
• GuoSHuangFGuoPConstruction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cellsGene Ther2006131081482016482206
   PubMed Web of Science ®Google Scholar
• LiuJGuoSCinierMFabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packagingACS Nano20105123724621155596
   PubMed Web of Science ®Google Scholar
• DavisMEZuckermanJEChoiCHJEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature201046472911067107020305636
   PubMed Web of Science ®Google Scholar
• KimSSPeerDKumarPRNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT miceMol Ther201018237037619997090
   PubMed Web of Science ®Google Scholar
• XinpingLApplications of RNA interference technology to drug studyChinese Pharmacological Bulletin2005214400403
   Google Scholar
• TheFreeLibrary.com [homepage on the Internet]OPKO Health Announces Update on Phase III Clinical Trial of BevasiranibPennsylvaniaFarlex, Inc.2012 [updated 2009 May 6; cited 2012 Apr 10]. Available from: http://www.thefreelibrary.com/OPKO+Health+Announces+Update+on+Phase+III+Clinical+Trial+of...-a0195014938. Accessed Jun 25, 2012.
   Google Scholar
• Quarkpharma.com [homepage on the Internet]Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3CaliforniaQuark Pharmaceuticals, Inc.2007 [updated 2009 May 11; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/arvo/. Accessed Jun 25, 2012.
   Google Scholar
• Tekmirapharm.com [homepage on the Internet]Tekmira Provides Corporate Update and Announces First Quarter 2012 ResultsBritish ColumbiaTekmira Pharmaceuticals Corp.2012 [updated 2012 May 15; cited 2012 Apr 10]. Available from: http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=673804. Accessed Jun 22, 2012
   Google Scholar
• Tekmirapharm.com [homepage on the Internet]Tekmira Announces Initiation of TKM-Ebola Phase 1 Clinical TrialBritish ColumbiaTekmira Pharmaceuticals Corp.2012 [updated 2012 Feb 8; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x541056/d731bed8-39f3-4fe2-a962-c86e2f72e681/TKMR_News_2012_2_8_General_Releases.pdf.Accessed Jun 24, 2012
   Google Scholar
• Pharmaceuticals A Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) In: Clinical-Trialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01065935?term=Alnylam&rank=5. ClinicalTrials.gov Identifier: NCT01065935. Accessed Jul 11, 2012
   Google Scholar
• Quarkpharma.com [homepage on the Internet]. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2012 Jan 4; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/newslist/clinicalstudyqpi-1007/. Accessed Jun 21, 2012.
   Google Scholar
• Pharmaceuticals A. Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement In: ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2011 [updated 2011 Aug 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT00882180?term=Alnylam&rank=3. ClinicalTrials.gov Identifier: NCT00882180. Accessed Jul 11, 2012
   Google Scholar
• Calando.com [homepage on the Internet]Arrowhead Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic Clinical Trial Results Published inNature CaliforniaCalando Pharmaceuticals2012 [updated 2010 Mar 22; cited 2012 Apr 11]. Available from: http://www.calandopharma.com/newspdfs/NR--Calando_data--3-22-10_final.pdf. Accessed Jun 19, 2012
   Google Scholar
• Project PC. Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita In: ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2008 [updated 2008 Nov 18]. Available from: http://clinicaltrials.gov/ct2/show/NCT00716014. ClinicalTrials.gov Identifier: NCT00716014. Accessed Jul 11, 2012.
   Google Scholar
• Genomeweb.com [homepage on the Internet]Allergan Drops Development of siRNA Rx for AMD on Poor Phase II DataNew YorkGenomeWeb LLC.2012 [updated 2009 May 28; cited 2012 Apr 11]. Available from: http://www.genomeweb.com/rnai/allergan-drops-development-sirna-rx-amd-poor-phase-ii-data. Accessed June 21, 2012
   Google Scholar
• Quarkpharma.com [homepage on the Internet]. QPI-1002. California: Quark Pharmaceuticals, Inc.; c 2007 [updated 2010 Aug 18; cited 2012 Apr 10]. Available from: http://www.quarkpharma.com/qbi-en/products/QPI-1002da/. Accessed Jun 15, 2012
   Google Scholar
• TheFreeLibrary.com [homepage on the Internet]. Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol. Pennsylvania: Farlex, Inc.; c 2012 [updated 2011 May 11; cited 2012 Apr 10]. Available from: http://www.thefreeli-brary.com/Santaris+Pharma+A%2fS+Advances+a+Second+Drug+From+Its+Cardiometabolic...-a0256048995. Accessed May 11, 2012
   Google Scholar
• Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) In: ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 Apr 20]. Available from: http://clinicaltrials.gov/ct2/show/NCT01437059?term=PCS02&rank=1. ClinicalTrials.gov Identifier: NCT01437059. Accessed Jul 11, 2012
   Google Scholar
• Santaris.com [homepage on the Internet]. Santaris Pharma A/S advances new cholesterol-lowering drug, SPC5001 inhibiting exciting new target PCSK9, into Phase 1 clinical trials for the treatment of high cholesterol. San Diego: Santaris Pharma A/S; c 2011 [updated 2011 May 4; cited 2012 Apr 9]. Available from: http://www.santaris.com/news/2011/05/04/santaris-pharma-advances-new-cholesterol-lowering-drug-spc5001-inhibiting-exciting-n. Accessed Jun 25, 2012
   Google Scholar
• Tekmirapharm.com [homepage on the Internet]. Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial. British Columbia: Tekmira Pharmaceuticals Corp.; c 2012 [updated 2010 Jan 7; cited 2012 Apr 10]. Available from: http://files.shareholder.com/downloads/ABEA-50QJTB/1754071349x0x425312/9b404e8f-82e2-48a8-ba61-7132-8539afd9/TKM_News_2010_1_7_General_Releases.pdf. Accessed Jun 29, 2012
   Google Scholar
• Giiresearch.com [homepage on the Internet]. Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy. Kawasaki: Global Information, Inc.; c 1997–2007 [updated 2011 Aug 12; cited 2012 Apr 11]. Available from: http://www.giiresearch.com/report/kt55538-therapy-prod.html. Accessed Jun 26, 2012
   Google Scholar
• Abnnewswire.net [homepage on the Internet]. rHIV7-shI-TAR-CCR5RZ. New York: ABN Newswire; c 2012 [updated 2010 Nov 1; cited 2012 Apr 11]. Available from: http://www.abnnewswire.net/search.asp?cp=utf-8&lang=_c&site=press_c&client=press-search-cs&output=xml_no_dtd&proxystylesheet=press-search-cs&proxyreload=1&filter=p&getfields=*&way=abn&way=web&qu=rHIV7-shI-TAR-CCR5RZ&stype=press_c&image2.x=33&image2.y=10. Accessed Jun 18, 2012.
   Google Scholar
• Pharmaceuticals A. Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis In: ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012 [updated 2012 May 23]. Available from: http://clinicaltrials.gov/ct2/show/NCT01148953?term=Alnylam&rank=4. ClinicalTrials.gov Identifier: NCT01148953. Accessed Jul 11, 2012.
   Google Scholar